Infliximab for the treatment of hidradenitis suppurativa

Hidradenitis suppurativa is a chronic inflammatory disease characterized by significant morbidity. Current medical therapies are usually only minimally effective.

To assess the efficacy and safety of infliximab monotherapy for the treatment of severe extensive refractory forms of hidradenitis suppurativa.

A retrospective study in a group of 6 patients who received treatment with infliximab for hidradenitis suppurativa, in the Dermatology Department of the University Hospital of Puerto Real in the last year. The dose was 5-10 mg/kg at weeks 0, 2 and 6, followed by a maintenance dose every 4 weeks. Subjective and objective efficacy was assessed before and after each treatment session.

All patients experienced improvement in subjective symptoms after the initial dose. A decrease in exudation, the size and number of lesions and less development of fistulous tracts were observed. The patients were followed up during 6 months. Treatment was generally well tolerated and there was only one mild reaction to the infusion in the form of headache. No patient required treatment discontinuation due to adverse effects.

Infliximab was shown to be an effective therapeutic alternative for severe extensive forms of hidradenitis suppurativa when it is used as monotherapy.